Suivre
Abonner Resverlogix Corp.

Resverlogix Corp.

Filtre
  • 07.04.2015 – 13:31

    Resverlogix Receives Two Patents for RVX-208 in China

    Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing ...

  • 15.01.2014 – 20:01

    Resverlogix Announces Combined RVX-208 Findings from SUSTAIN & ASSURE Phase 2b Trials

    Calgary, Alberta (ots/PRNewswire) - "RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX Resverlogix Corp. today announced new information arising from its ongoing analysis of data from both the SUSTAIN and ASSURE trials in atherosclerotic patients with high risk for recurrent events. This analysis, performed ...

  • 29.08.2013 – 15:02

    Resverlogix Announces a Corporate Update Conference Call & Webcast

    Calgary, Alberta (ots/PRNewswire) - TSX Exchange Symbol: RVX Resverlogix Corp. today announced they will be hosting a corporate update conference call and webcast with Q&A on September 3rd at 11 am MDT. Details for the conference call and webcast are as follows: Link to webcast: http://services.choruscall.ca/links/resverlogix130905.html Dial in numbers: Canada & USA Toll Free Dial In: 1-800-319-4610 Outside of Canada & ...

  • 18.04.2013 – 13:02

    Resverlogix Completes Dosing in ASSURE Clinical Trial

    Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low ...

  • 08.04.2013 – 13:01

    Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders

    Calgary, Canada (ots/PRNewswire) - Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") today announced that its Board of Directors has approved a proposal to spin-out its subsidiary, RVX Therapeutics Inc. ("RVX Therapeutics"), which will focus on innovative drug research and development by leveraging its epigenetics ...

  • 26.09.2012 – 13:32

    Resverlogix Completes Enrollment in ASSURE Trial

    Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with Coronary Artery Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients. ASSURE will evaluate the ability of RVX-208, Resverlogix's BET protein inhibitor, to regress atherosclerotic disease versus ...

  • 23.04.2012 – 13:32

    Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials

    Calgary, Alberta (ots/PRNewswire) - This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Our data shows RVX-208 to be an inhibitor of the Bromodomain and ...

  • 19.04.2012 – 15:03

    Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action

    Calgary, Alberta (ots/PRNewswire) - Dr. Stephen J. Nicholls joins as guest speaker TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") is pleased to announce for the first time the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Please join us via Conference Call & Webcast on Monday, April 23, 2012, ...